

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

April 08, 2025

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
--	--

Sub: Disclosure under of SEBI (LODR) Regulations, 2015 “Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval to Market Teriflunomide Tablets, 7 mg and 14 mg, in the US

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has been granted final approval from the United States Food and Drug Administration (USFDA) for marketing its Teriflunomide Tablets, 7 mg and 14 mg. Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.

This approval reinforces our capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market. According to IQVIA™, the market size of Teriflunomide tablets is approximately \$402 million in the US, and the global market size is approximately \$908 million, indicating significant opportunities for expansion in the US and the global market.

This intimation is being submitted for your information and records please.

Thanking You

For Concord Biotech Limited

Prakash Sajnani

Company Ssecretary and Compliance Officer

M. No. F6242